By Max Rex, Associate Consultant Email: mrex@partners4access.com Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green light by the European Medicines Agency on 19th May. The therapy has previously been approved in the US and Japan, and has already generated sales of over $500 million dollars…
Partners4Access has announced their gold sponsorship of the biotech industry conference World Orphan Drug Congress (WODC) USA. The event will take place at The Gaylord National Harbor Hotel in Oxon Hill, Maryland between April 10-12, 2019. The P4A team will be involved in three main segments of WODC: Sophie Schmitz, Managing Partner will be moderating…
A US and EU perspective By Daniele Severi Bruni & Sophie Schmitz What’s the idea? Payer concerns over increasing cost of therapies and uncertainty of clinical data has led to a growing interest in market access tools. Experts Daniele Severi Bruni partner at MKO and Sophie Schmitz from Partners4Access discuss this potential payer solution for…
Everything you need to know about the latest Brexit White Paper By Joanna Fernandes, Analyst Email: jfernandes@partners4access.com As the countdown to Brexit draws near, a flurry of activities has emerged from the UK government, the EU and the pharma/biotech industry. But central to the conversation is the recent white paper released by the UK government…
Partners4Access has announced the appointment of Alison Kneen as Vice President of International Operations to lead its rapidly expanding Market Access Orphan Drug Specialist team. Alison brings extensive international market access experience built over the last 27 years from previous roles with IQVIA; Principal and Head of Market Access Strategic Consulting, as well as during…